Current treatment of atypical hemolytic uremic syndrome

Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaplan, Bernard S., Ruebner, Rebecca L., Spinale, Joann M., Copelovitch, Lawrence
Format: Artigo
Idioma:Inglês
Publicat: International Research and Cooperation Association for Bio & Socio-Sciences Advancement 2014
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/
https://ncbi.nlm.nih.gov/pubmed/25343125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars